By: Christopher Parrella, Esq., CPC, CHC, CPCO Parrella Health Law, Boston, MA. A Health Care Provider Defense and Compliance Firm

The HHS Office of Inspector General (OIG) just issued Advisory Opinion 25-09, a favorable ruling for a physician-owned medical device company that manufactures stroke-treatment products. The headline: physician ownership can avoid Anti-Kickback Statute (AKS) risk if the arrangement lands squarely inside the small entity investment safe harbor at 42 C.F.R. § 1001.952(a)(2).

What OIG blessed

OIG concluded the company’s physician-owner model did not generate prohibited remuneration under the AKS because the company certified it met every condition of the small entity investment safe harbor. Key facts OIG relied on included: physician investors held ~35% of the company (under the 40% cap), investment terms for physicians matched those for non-referring passive investors, no “refer-to-stay” expectations, no loans to help physicians buy in, revenue from investor-generated business stayed under 40%, and any future distributions would be pro rata to capital invested.

Translation: this was a textbook safe-harbor build: precise certifications, hard caps, even-handed terms, and no pay-to-play features.

Why this matters to clinicians, ASCs, and device startups

Physician-owned entities that sell devices their owners may use are a perennial OIG concern (see OIG’s 2013 Special Fraud Alert on PODs). OIG pointed out those concerns here but said this specific arrangement is protected because it precisely satisfies the small entity investment safe harbor. That’s a narrow lane: miss one condition and you’re back to case-by-case AKS risk.

The eight safe-harbor gates you must clear

If you’re structuring (or auditing) an investment in a device, DME, or health-tech company, these are the non-negotiables OIG highlighted:

1. Ownership concentration: ≤ 40% of each class of investment interests may be held (in the prior 12 months) by referral-capable investors.
2. Parity of terms: Physician/passive investors get the same offering terms as other passive investors.
3. No volume/value linkage: Offer terms aren’t tied to past or expected referrals, items, services, or business generated.
4. No refer-to-stay: Remaining an investor cannot be conditioned on the ability or willingness to refer or generate business.
5. No special treatment: The company (or its investors) doesn’t market or furnish items/services to investor-physicians differently than to non-investors.
6. Revenue mix cap: ≤ 40% of the entity’s health-care revenue (past 12 months) comes from investor-generated business.
7. No financed buy-ins: Neither the entity nor any investor lends or guarantees funds for referral-capable investors to purchase interests.
8. Pro-rata returns only: Payments to investors are directly proportional to capital invested (including FMV of pre-operational services).

Meet all eight, and you’re inside the safe harbor. Miss one, and you’re outside where OIG has warned physician-owned entities can be “inherently suspect,” especially when investors can steer cases, pressure hospitals, or reap outsized, low-risk returns.

Practical takeaways for the health care industry

• Device makers & health-tech startups: Build your cap table with the 40/40 rules in mind (ownership and revenue from investor-generated business). Lock in uniform term sheets and memorialize the absence of any volume/value linkage.
• Physician groups & ASCs: Before you invest, demand written certifications that each safe-harbor element is satisfied now and monitored quarterly. Require pro-rata distribution policies and prohibit entity-financed buy-ins.
• Hospitals & supply-chain leaders: If physicians have device ownership, confirm there’s no explicit or implicit pressure to purchase those products; document clinical-value procurement decisions independent of ownership.
• Compliance officers: Audit for drift. Ownership and revenue percentages are rolling 12-month metrics. Today’s compliance can slip tomorrow without monitoring, especially after growth rounds or M&A.

Caution labels still apply

OIG’s opinion is fact-specific, binds only the requestor, and doesn’t address Stark or False Claims Act risk from downstream billing. OIG also reserves the right to rescind if material facts change. Treat this as a blueprint, not a hall pass. OIG just showed how physician ownership in a device company can be structured to comply with the AKS but only inside the small entity investment safe harbor, with documentation and ongoing surveillance to match. If you’re considering an investment or cleaning up one you already have now is the time to tighten terms, test the numbers, and formalize monitoring.

Need a rapid safe-harbor audit or re-papering of your investment documents? Parrella Health Law can help you operationalize these requirements without stifling innovation. Contact us at 857-328-0382 or Chris directly at cparrella@parrellahealthlaw.com.

This post is for informational purposes only and does not constitute legal advice.